Advertisement

Beneficial effect of a mixture of vitamin-producing and immune-modulating lactic acid bacteria as adjuvant for therapy in a recurrent mouse colitis model

  • Romina Levit
  • Graciela Savoy de Giori
  • Alejandra de Moreno de LeBlancEmail author
  • Jean Guy LeBlancEmail author
Applied microbial and cell physiology
  • 35 Downloads

Abstract

Inflammatory bowel diseases are chronic and relapsing-remitting disorders that affect the gastrointestinal tract. Previously, the administration of folate and riboflavin-producing lactic acid bacteria (LAB) or an immune-modulating strain showed beneficial effects as they were able to reduce the acute inflammation in mouse models. The aim of this work was to evaluate a mixture of vitamin-producing and immune-modulating LAB administering together with an anti-inflammatory drug during the remission period of a mouse model of recurrent colitis. BALB/c mice were intrarectally instilled with trinitrobenzene sulfonic acid (TNBS) and those who recovered from this acute challenge were given the LAB mixture, mesalazine, or the combination of both (mesalazine + LAB) during 21 days, followed by a second challenge with TNBS. Control mice instilled with ethanol (vehicle of TNBS) and receiving the different treatments were also evaluated in order to study the effect of chronic anti-inflammatory therapy. The combination of mesalazine and LAB mixture was the most effective to decrease the intestinal damage at macroscopic and histological levels and to reduce pro-inflammatory cytokines (IL-6 and TNF-α) in intestinal fluids. In animals instilled with ethanol, mesalazine produced a loss of body weight and intestinal damages with increased IL-6. These side effects were prevented by the co-administration of mesalazine and the LAB mixture. The LAB blend did not affect the primary anti-inflammatory treatment, was able to improve it, and also prevented the side effects of this therapy.

Keywords

Folate Riboflavin Immune modulation Anti-inflammatory therapy Recurrent colitis 

Notes

Funding information

This work was financially supported by CONICET (Consejo Nacional de Investigaciones Científicas y Técnicas projects PIP006 and 0697) and ANPCyT (Agencia Nacional de Promoción Científica y Tecnológica projects 0301, 2554, 2859, and 3045).

Compliance with ethical standards

Conflict of interest

The authors declare that there are no conflicts of interest.

Ethical approval

Animal experiments were approved by the Animal Protection Committee of CERELA and all experiments comply with the current laws of Argentina and international organizations for the use of experimental animals.

References

  1. Abraham BP, Quigley EMM (2017) Probiotics in inflammatory bowel disease. Gastroenterol Clin 46(4):769–782CrossRefGoogle Scholar
  2. Ameho CK, Adjei AA, Harrison EK, Takeshita K, Morioka T, Arakaki Y, Ito E, Suzuki I, Kulkarni AD, Kawajiri A (1997) Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor α production in trinitrobenzene sulphonic acid induced colitis. Gut 41(4):487–493CrossRefGoogle Scholar
  3. Ashton JJ, Mossotto E, Ennis S, Beattie RM (2019) Personalising medicine in inflammatory bowel disease-current and future perspectives. Transl Pediatr 8(1):56–69CrossRefGoogle Scholar
  4. Bjarnason I, Scarpignato C, Holmgren E, Olszewski M, Rainsford KD, Lanas A (2018) Mechanisms of damage to the gastrointestinal tract from nonsteroidal anti-inflammatory drugs. Gastroenterology 154(3):500–514CrossRefGoogle Scholar
  5. Cenac N, Coelho A-M, Nguyen C, Compton S, Andrade-Gordon P, MacNaughton WK, Wallace JL, Hollenberg MD, Bunnett NW, Garcia-Villar R (2002) Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am J Pathol 161(5):1903–1915CrossRefGoogle Scholar
  6. Chae JM, Chang MH, Heo W, Cho HT, Lee DH, Hwang BB, Kim JW, Yoon SM, Yang S, Lee JH (2019) LB-9, novel probiotic lactic acid bacteria, ameliorates dextran sodium sulfate-induced colitis in mice by inhibiting TNF-α mediated apoptosis of intestinal epithelial cells. J Med Food 22(3):271–276CrossRefGoogle Scholar
  7. Chaves S, Perdigon G, de Moreno de LeBlanc A (2011) Yoghurt consumption regulates the immune cells implicated in acute intestinal inflammation and prevents the recurrence of the inflammatory process in a mouse model. J Food Prot 74(5):801–811CrossRefGoogle Scholar
  8. del Carmen S, de Moreno de LeBlanc A, Martin R, Chain F, Langella P, Bermúdez-Humarán LG, LeBlanc JG (2014) Genetically engineered immunomodulatory Streptococcus thermophilus strains producing antioxidant enzymes exhibit enhanced anti-inflammatory activities. App Environ Microbiol 80(3):869–877CrossRefGoogle Scholar
  9. del Carmen S, de Moreno de LeBlanc A, LeBlanc JG (2016) Development of a potential probiotic yoghurt using selected anti-inflammatory lactic acid bacteria for prevention of colitis and carcinogenesis in mice. J Appl Microbiol 121(3):821–830CrossRefGoogle Scholar
  10. del Carmen S, de Moreno de LeBlanc A, Levit R, Azevedo V, Langella P, Bermúdez-Humarán LG, LeBlanc JG (2017) Anti-cancer effect of lactic acid bacteria expressing antioxidant enzymes or IL-10 in a colorectal cancer mouse model. Int Immunopharmacol 42:122–129CrossRefGoogle Scholar
  11. Derwa Y, Gracie DJ, Hamlin PJ, Ford AC (2017) Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. Aliment Pharmacol Ther 46(4):389–400CrossRefGoogle Scholar
  12. Ganji-Arjenaki M, Rafieian-Kopaei M (2018) Probiotics are a good choice in remission of inflammatory bowel diseases: a meta analysis and systematic review. J Cell Physiol 233(3):2091–2103CrossRefGoogle Scholar
  13. Hoffmann M, Schwertassek U, Seydel A, Weber K, Falk W, Hauschildt S, Lehmann J (2018) A refined and translationally relevant model of chronic DSS colitis in BALB/c mice. Lab Anim 52(3):240–252CrossRefGoogle Scholar
  14. Johnson AJ, Vangay P, Al-Ghalith GA, Hillmann BM, Ward TL, Shields-Cutler RR, Kim AD, Shmagel AK, Syed AN, Personalized Microbiome Class Students, Walter J, Menon R, Koecher K, Knights D (2019) Daily sampling reveals personalized diet-microbiome associations in humans. Cell Host Microbe 25(6):789–802CrossRefGoogle Scholar
  15. Juárez del Valle M, Laiño JE, Savoy de Giori G, LeBlanc JG (2014) Riboflavin producing lactic acid bacteria as a biotechnological strategy to obtain bio-enriched soymilk. Food Res Int 62:1015–1019CrossRefGoogle Scholar
  16. Klein A, Eliakim R (2010) Non steroidal anti-inflammatory drugs and inflammatory bowel disease. Pharmaceuticals 3(4):1084–1092CrossRefGoogle Scholar
  17. Kvasnovsky CL, Aujla U, Bjarnason I (2015) Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease. Scand J Gastroenterol 50(3):255–263CrossRefGoogle Scholar
  18. Laiño JE, LeBlanc JG, Savoy de Giori G (2012) Production of natural folates by lactic acid bacteria starter cultures isolated from artisanal Argentinean yogurts. Can J Microbiol 58(5):581–588CrossRefGoogle Scholar
  19. Levit R, Savoy de Giori G, de Moreno de LeBlanc A, LeBlanc JG (2017a) Effect of riboflavin-producing bacteria against chemically induced colitis in mice. J Appl Microbiol 124(1):232–240CrossRefGoogle Scholar
  20. Levit R, Savoy de Giori G, de Moreno de LeBlanc A, JG LB (2017b) Evaluation of the effect of soymilk fermented by a riboflavin-producing Lactobacillus plantarum train in a murine model of colitis. Benef Microbes 8(1):65–72CrossRefGoogle Scholar
  21. Levit R, Savoy de Giori G, de Moreno de LeBlanc A, JG LB (2018a) Protective effect of the riboflavin-overproducing strain Lactobacillus plantarum CRL 2130 on intestinal mucositis in mice. Nutrition 54:165–172CrossRefGoogle Scholar
  22. Levit R, Savoy de Giori G, de Moreno de LeBlanc A, LeBlanc JG (2018b) Folate-producing lactic acid bacteria reduce inflammation in mice with induced intestinal mucositis. J Appl Microbiol 125(5):1494–1501CrossRefGoogle Scholar
  23. Levit R, Savoy de Giori G, de Moreno de LeBlanc A, LeBlanc JG (2018c) Increasing B vitamins in foods to prevent intestinal inflammation and cancer nutrients in dairy and their implications on health and disease. Elsevier:193–204Google Scholar
  24. Mallick H, Franzosa EA, Mclver LJ, Banerjee S, Sirota-Madi A, Kostic AD, Clish CB, Vlamakis H, Xavier RJ, Huttenhower C (2019) Predictive metabolomic profiling of microbial communities using amplicon or metagenomic sequences. Nat Commun 10(1):3136CrossRefGoogle Scholar
  25. Mardini HE, Grigorian AY (2014) Probiotic mix VSL#3 is effective adjunctive therapy for mild to moderately active ulcerative colitis: a meta-analysis. Inflamm Bowel Dis 20(9):1562–1567CrossRefGoogle Scholar
  26. Masson EA, Rhodes JM (1992) Mesalazine associated nephrogenic diabetes insipidus presenting as weight loss. Gut 33(4):563–564CrossRefGoogle Scholar
  27. Palma E, Costa N, Molinaro R, Francardi M, Paolino D, Cosco D, Fresta M (2019) Improvement of the therapeutic treatment of inflammatory bowel diseases following rectal administration of mesalazine-loaded chitosan microparticles vs Asamax®. Carbohydr Polym 212:430–438CrossRefGoogle Scholar
  28. Plichta DR, Graham DB, Subramanian S, Xavier RJ (2019) Therapeutic opportunities in inflammatory bowel disease: mechanistic dissection of host-microbiome relationships. Cell 178(5):1041–1056CrossRefGoogle Scholar
  29. Saez-Lara MJ, Gomez-Llorente C, Plaza-Diaz J, Gil A (2016) The role of probiotic lactic acid bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: a systematic review of randomized human clinical trials. Biomed Res Int 2015:1–15.  https://doi.org/10.1155/2015/505878 CrossRefGoogle Scholar
  30. Sann H, von Erichsen J, Hessmann M, Pahl A, Hoffmeyer A (2013) Efficacy of drugs used in the treatment of IBD and combinations thereof in acute DSS-induced colitis in mice. Life Sci 92(12):708–718CrossRefGoogle Scholar
  31. Wang CS, Li WB, Wang HY, Ma YM, Zhao XH, Yang H, Qian JM, Li JN (2018) VSL#3 can prevent ulcerative colitis-associated carcinogenesis in mice. World J Gastroenterol 24(37):4254–4262CrossRefGoogle Scholar
  32. Wasilewska E, Zlotkowska D, Wroblewska B (2019) Yogurt starter cultures of Streptococcus thermophilus and Lactobacillus bulgaricus ameliorate symptoms and modulate the immune response in a mouse model of dextran sulfate sodium-induced colitis. J Dairy Sci 102(1):37–53CrossRefGoogle Scholar
  33. WHO FAO (2002) Probiotics in food health and nutritional properties and guidelines for evaluation. Food and Agriculture Organization of the United Nations and World Health Organization Expert Consultation Report. http://www.fao.org/3/a-a0512e.pdf. Accessed 29 July 2019
  34. Wirtz S, Popp V, Kindermann M, Gerlach K, Weigmann B, Fichtner-Feigl S, Neurath MF (2017) Chemically induced mouse models of acute and chronic intestinal inflammation. Nat Protoc 12(7):1295–1309CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Centro de Referencia para Lactobacilos (CERELA-CONICET)TucumánArgentina
  2. 2.Cátedra de Microbiología Superior, Facultad de Bioquímica, Química y FarmaciaUniversidad Nacional de TucumánTucumánArgentina

Personalised recommendations